Vericiguat - Bayer HealthCare Pharmaceuticals/Merck & Co
Alternative Names: BAY 102; BAY-1021189; MK-1242; VERQUVOLatest Information Update: 08 Oct 2024
At a glance
- Originator Bayer HealthCare Pharmaceuticals
- Developer Bayer HealthCare Pharmaceuticals; Merck & Co
- Class Amines; Carbamates; Fluorobenzenes; Heart failure therapies; Pyrazoles; Pyridines; Pyrimidines; Small molecules; Vasodilators
- Mechanism of Action Guanylate cyclase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic heart failure
- Phase II Metabolic syndrome
- No development reported Coronary artery disease
Most Recent Events
- 01 Oct 2024 Phase-II/III clinical trials in Chronic heart failure (In adolescents, In children, In infants, In neonates) in Mexico (PO) (NCT05714085)
- 29 Jul 2024 Bayer completes a phase IIb trial for Chronic heart failure in USA, Argentina, Hungary, Italy, Poland, Spain, Sweden (PO, Tablet) (NCT06195930)
- 03 Jul 2024 Phase-III clinical trials in Chronic heart failure (In adolescents, In adults, In children, In infants, In the elderly) in USA, Hungary (PO) (NCT06428383)